Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Invion ( (AU:IVX) ) is now available.
Invion Limited has addressed a query from the ASX regarding the timing of its cleansing notice related to its Phase I/II trial for non-melanoma skin cancer. The company confirmed that the trial showed no adverse events and that the treatment was well tolerated with observable reductions in lesion size, marking a significant advancement over existing PDT treatments. This development is crucial for Invion’s market positioning as it demonstrates the potential efficacy and safety of its treatment, which could enhance investor confidence and stakeholder interest.
More about Invion
Invion Limited operates in the biotechnology industry, focusing on the development of Photodynamic Therapy (PDT) treatments for non-melanoma skin cancer (NMSC). The company is engaged in clinical trials to advance its therapeutic solutions in this niche market.
Average Trading Volume: 102,006
Technical Sentiment Signal: Sell
Current Market Cap: A$10.17M
See more data about IVX stock on TipRanks’ Stock Analysis page.